PNC Financial Services Group
AIM

PNC Financial Services Group’s AIM ImmunoTech AIM Stock Holding History

PNC Financial Services Group’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$137 – 5350
2025
Q3 		$137 Buy
+50
New +$224 ﹤0.01% 4970

Other funds holding AIM

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CB
Community Bank Dewitt, New York $840M AUM 22.23% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HI
Hoey Investments Coatesville, Pennsylvania $774M AUM 27.34% 1-Year Est. Return

PNC Financial Services Group's AIM Position: Q4 2025 in Review

PNC Financial Services Group sold out of AIM ImmunoTech (AIM) in Q4 2025, closing a stake of 50 shares — an estimated $137 sold.

PNC Financial Services Group first reported a position in AIM in Q3 2025 and held it in 1 quarter. The position peaked at $137 in Q3 2025. 13 funds tracked by Wall St. Rank hold AIM as of Q4 2025.

  • PNC Financial Services Group reported no remaining AIM ImmunoTech position as of Q4 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 50 AIM ImmunoTech shares in Q4 2025, an estimated $137.
  • PNC Financial Services Group first reported a position in AIM ImmunoTech in Q3 2025 and held it in 1 quarter.
  • PNC Financial Services Group's AIM ImmunoTech position peaked at $137 in Q3 2025.
  • 13 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2025.

Based on PNC Financial Services Group's 13F filing for Q4 2025, filed 6 Feb 2026.